StockTipsArenaBeta

SELL Dr. Lal Path Labs Ltd. — Goldman Sachs

SELLDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)5 Nov 2026via ET Now (Live)

Entry₹2,049Inferred
Target₹1,750
Total upside +14.59%
Stop lossNot given
CMP₹1,9701d ago
Active+3.86%+11.17%upside left 12 mo left
Follow Goldman Sachs for new calls(100% target hit, 40 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 6 other Long-term calls on LALPATHLABSee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST
1 supporting2 neutral16 opposing
Supports the SELL call (1)

1 other SEBI-registered advisor has an active long-term SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·5 Nov · 2d ago

Neutral / worth noting (2)

Dr. Lal PathLabs' subsidiary, PathLabs Unifiers Private Limited, has acquired the remaining 30% stake in Centrapath Labs Private Limited, making it a wholly owned subsidiary.

BSE · Company Update·13 Oct · 3w ago

(opens in new tab)

Dr. Lal PathLabs invested up to INR 30.3 crores in its wholly owned subsidiary, PathLabs Unifiers Private Limited, to fund the acquisition of the remaining 30% stake in CentraPath Labs Private Limited

BSE · Company Update·12 Oct · 4w ago

(opens in new tab)
Weighs against the SELL call (16)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

5 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·5 Nov · 2d ago

Dr. Lal PathLabs reported Q2 FY27 consolidated revenue of Rs 874 Cr, up 19.6% YoY, with PAT of Rs 194 Cr, up 27.5% YoY. The company also declared an interim dividend of Rs 5 per share.

NSE · Press Release·4 Nov · 3d ago

(opens in new tab)

Dr. Lal PathLabs reported Q2 FY27 consolidated revenue of Rs 874 Cr, up 19.6% YoY, with PAT increasing 27.5% to Rs 194 Cr. The company also declared an interim dividend of Rs 5 per share.

BSE · Company Update·4 Nov · 3d ago

(opens in new tab)

The company reported financial results for the quarter and half-year ended September 30, 2026, declared a second interim dividend of INR 5 per share, and announced a further investment of INR 49.5 cro

BSE · Company Update·4 Nov · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Goldman Sachs

Every call and its outcome